Valitor News Archive:
September 12, 2017
Valitor has been awarded a Phase I SBIR grant from the National Institute of Arthritis and Musculoskeletal and Skin Diseases. This project will support the translation platform technology to generate long-acting drug products that can be used to treat inflammatory joint diseases.
May 8, 2017
Valitor presented the its first preclinical data at the 2018 Associate for Research in Vision and Ophthalmology conference in Baltimore, MD. This report demonstrated a substantial increase in intravitreal half-life and extended efficacy for their lead Anti-VEGF compound intended to treat indications in ophthalmology.
December 13, 2016
Valitor was awarded the 2016 PharmaDirections Jumpstart Grant for California, presented at the California Life Sciences Institute's Fall Showcase event. This award recognizes one California start up company in the Life Sciences each year that is likely to make a significnat impact on their target market. The award includes consulting and project management that will help us develop a product development and viable commercial plan.
September 8, 2016
Valitor has been awarded a Phase I SBIR grant from the National Eye Institute. This project is designed to apply our technology towards localized and sustained treatments in ophthalmology. Specifically, we will validate a long-acting anti-VEGF drug to treat diabetic macular edema.
June 1, 2016
Valitor has recruited and hired Livia Brier, PhD to join our team as Director of Nonclinical research. Livia is a recent graduate from UC Berkeley’s Molecular and Cell Biology doctoral program with extensive experience in biochemistry and cell biology. She will be applying her experience in protocol development towards our expanding in vivo studies.
May 16, 2016
Valitor will be attending this year's BIO International Convention June 6-9 in San Francisco as a part of the NIH Innovation Zone. We were selected for this opportunity by the NIH to highlight the technologies under development using Phase II NIH SBIR Awards. We look forward to meeting with potential development partners, CROs, CMOs. Please stop by our kiosk (at booth 7253) if you are going to be there!
April 1, 2016
Valitor has been awarded a Phase I SBIR grant from the National Institute of General Medical Sciences. This project will support the translation of our wound healing platform to a wider range of growth factors and other therapeutic proteins that have demonstrated safety in previous clinical studies. The results of this award will facilitate strategic partnerships and commercialization of our technology.
October 28, 2015
Valitor has been accepted into the Spring 2016 cohort at SkyDeck. SkyDeck is a joint venture of UC Berkeley’s College of Engineering, the Haas School of Business, and the Vice Chancellor for Research Office. This unique ecosystem, is designed to give startup companies the opportunity to launch and compete with industry leaders.
October 7, 2015
Valitor, Inc. has been selected into the 2015-16 NIH SBIR/STTR Commercialization Accelerator Program (CAP) for Phase II awardees. The CAP is a technical assistance program to help efficiently move NIH-funded technology towards commercialization. It is co-sponsored by the LARTA institute, which offers accelerator programs for entrepreneur and commercialization training to startup companies and university spin outs.
July 30, 2015
Valitor has been selected to participate in the Fall 2015 session of the All Stars FAST Advisory Program. The FAST program is sponsored by the California Life Sciences Institute and provides select entrepreneurs with intensive team review and coaching to perfect their business model, product development plans, and to build a compelling commercialization strategy.
December 1, 2014
Valitor has recruited and hired Mavish Mahomed to join our team as a research associate. Mavish is a recent graduate of the UC Davis department of Biochemistry and Cell Biology. She has extensive experience in methods of protein synthesis and characterization. She will apply her knowledge in these areas to expand our protein conjugation platform and to develop bioassays to validate their capabilities.
May 1, 2014:
Valitor has been awarded a Phase II SBIR grant from the National Institute of Arthritis and Musculoskeletal and Skin Diseases. This project will enable us to refine an IND-candidate for our lead compound, as well as to identify additional related applications for our multivalent protein conjugation technology.
August 12, 2013:
Valitor has been awarded a Phase I SBIR grant from the National Institute of General Medical Sciences. This project is designed to investigate the use of our multivalent protein technology to accelerate wound closure for a wider set of indications related to impaired wound healing.
October 22, 2012:
Valitor, Inc. has successfully recruited and hired Taylor Holstlaw to join our team as a research associate. Taylor has worked for life sciences startup companies since graduating from the UC Berkeley Department of Bioengineering, and she will apply her experience in assay development and process optimization to the R&D for our multivalent protein conjugate technology.
September 10, 2012:
Valitor, Inc. has been awarded a Phase I SBIR grant from the National Institute of Arthritis and Musculoskeletal and Skin Diseases. This project is designed to evaluate proof-of-concept for our multivalent protein conjugation technology to accelerate wound closure for patients who exhibit impaired wound healing associated with diabetes.